FY2025 Earnings Estimate for AbbVie Issued By Zacks Research

AbbVie Inc. (NYSE:ABBV) – Equities researchers at Zacks Research lifted their FY2025 EPS estimates for AbbVie in a note issued to investors on Tuesday, February 18th. Zacks Research analyst S. Ganoria now forecasts that the company will post earnings per share of $12.14 for the year, up from their previous estimate of $11.94. The consensus estimate for AbbVie’s current full-year earnings is $12.32 per share. Zacks Research also issued estimates for AbbVie’s Q4 2025 earnings at $3.39 EPS, Q4 2026 earnings at $3.77 EPS and FY2026 earnings at $13.57 EPS.

Other equities analysts have also issued research reports about the stock. Daiwa America lowered shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 5th. Leerink Partnrs raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 22nd. Daiwa Capital Markets cut shares of AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 target price for the company. in a research note on Thursday, December 5th. Bank of America reiterated a “neutral” rating and set a $191.00 target price on shares of AbbVie in a research note on Tuesday, December 10th. Finally, Morgan Stanley upped their target price on shares of AbbVie from $224.00 to $239.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $208.35.

AbbVie Trading Up 1.8 %

NYSE:ABBV opened at $200.98 on Friday. AbbVie has a 12 month low of $153.58 and a 12 month high of $207.32. The firm has a market cap of $354.80 billion, a price-to-earnings ratio of 83.74, a P/E/G ratio of 1.58 and a beta of 0.58. The company has a quick ratio of 0.54, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. The company’s 50 day moving average is $180.68 and its 200-day moving average is $186.29.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same quarter in the prior year, the business posted $2.79 EPS.

Institutional Investors Weigh In On AbbVie

A number of hedge funds have recently added to or reduced their stakes in ABBV. AlphaCore Capital LLC lifted its position in AbbVie by 0.9% during the 4th quarter. AlphaCore Capital LLC now owns 19,509 shares of the company’s stock valued at $3,467,000 after purchasing an additional 182 shares during the period. Mackenzie Financial Corp lifted its position in AbbVie by 58.2% during the 4th quarter. Mackenzie Financial Corp now owns 3,682,224 shares of the company’s stock valued at $654,331,000 after purchasing an additional 1,353,971 shares during the period. Forum Financial Management LP lifted its position in AbbVie by 11.4% during the 4th quarter. Forum Financial Management LP now owns 58,788 shares of the company’s stock valued at $10,447,000 after purchasing an additional 6,036 shares during the period. Griffith & Werner Inc. acquired a new position in AbbVie during the 4th quarter valued at about $1,924,000. Finally, Sunbeam Capital Management LLC acquired a new position in AbbVie during the 4th quarter valued at about $692,000. Institutional investors own 70.23% of the company’s stock.

Insider Transactions at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the sale, the senior vice president now owns 6,983 shares of the company’s stock, valued at $1,202,751.92. This represents a 20.49 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.25% of the stock is owned by insiders.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be issued a $1.64 dividend. This represents a $6.56 annualized dividend and a dividend yield of 3.26%. The ex-dividend date of this dividend is Tuesday, April 15th. AbbVie’s payout ratio is 273.33%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.